文献速递糖尿病

密歇根神经病变筛查量表三问题集为心血管结局提供独立预后信息:ALTITUDE试验分析

Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trial.
PubMed 文献 · Diabetologia · 2017-11-03

本研究为ALTITUDE试验的事后分析,纳入8463例2型糖尿病合并慢性肾脏病和/或心血管疾病的患者,分为训练集3252例和验证集5211例。训练集识别出MNSI中三个与心血管复合结局显著相关的问题,验证集显示一个及以上阳性回答与心血管复合结局、心衰住院、心梗、卒中及三点MACE风险升高相关,且加入阳性回答总数可改善风险预测模型。

要点

  • MNSI三问题(腿麻、足部开放伤口、行走腿痛)在训练集中与心血管复合结局显著相关。
  • 验证集中一个及以上阳性回答(59.1%)与心血管复合结局风险升高相关(HR 1.54)。
  • 三个问题均阳性(11%)时关联更强,加入阳性回答数可改善Harrell's C统计量等预测指标。

核心结论

  • 从MNSI中识别出三个问题可为2型糖尿病合并CKD和/或CVD患者提供额外预后信息;若经外部验证,这些问题可能整合入临床病史以增强高危患者心血管事件预测。

研究设计与样本

  • ALTITUDE试验的事后分析,纳入8463例2型糖尿病合并慢性肾脏病和/或心血管疾病患者,分为训练集3252例和验证集5211例。

主要发现

  • 训练集中三个问题(「您的腿麻木吗?」「您足部是否出现过开放伤口?」「您行走时腿痛吗?」)与心血管复合结局显著相关。
  • 验证集中,一个及以上阳性回答(n=3079,59.1%)相较于所有问题均无阳性回答,与心血管复合结局风险升高相关(HR 1.54 [95% CI 1.28, 1.85],p < 0.001)。
  • 一个及以上阳性回答与心衰住院(HR 1.74 [95% CI 1.29, 2.35],p < 0.001)、心肌梗死(HR 1.81 [95% CI 1.23, 2.69],p = 0.003)、卒中(HR 1.75 [95% CI 1.20, 2.56],p = 0.003)及三点MACE(HR 1.49 [95% CI 1.20, 1.85],p < 0.001)风险升高相关。
  • 三个问题均阳性(n=552,11%)时关联更强。
  • 将阳性回答总数加入现有模型显著改善心血管复合结局的Harrell's C统计量(0.70 vs 0.71,p = 0.010)、连续净重分类改善(+22% [+10%, +31%],p = 0.027)和综合判别改善(+0.9% [+0.4%, +2.1%],p = 0.007)。

临床怎么用

  • 作者认为,若经外部验证,这三个问题可能整合入临床病史以增强高危2型糖尿病患者心血管事件预测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The self-administered Michigan Neuropathy Screening Instrument (MNSI) is used to diagnose diabetic peripheral neuropathy. We examined whether the MNSI might also provide information on risk of death and cardiovascular outcomes. METHODS: In this post hoc analysis of the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) trial, we divided 8463 participants with type 2 diabetes and chronic kidney disease (CKD) and/or cardiovascular disease (CVD) into independent training (n = 3252) and validation (n = 5211) sets. In the training set, we identified specific questions that were independently associated with a cardiovascular composite outcome (cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction/stroke, heart failure hospitalisation). We then evaluated the performance of these questions in the validation set. RESULTS: In the training set, three questions ('Are your legs numb?', 'Have you ever had an open sore on your foot?' and 'Do your legs hurt when you walk?') were significantly associated with the cardiovascular composite outcome. In the validation set, after multivariable adjustment for key covariates, one or more positive responses (n = 3079, 59.1%) was associated with a higher risk of the cardiovascular composite outcome (HR 1.54 [95% CI 1.28, 1.85], p < 0.001), heart failure hospitalisation (HR 1.74 [95% CI 1.29, 2.35], p < 0.001), myocardial infarction (HR 1.81 [95% CI 1.23, 2.69], p = 0.003), stroke (HR 1.75 [95% CI 1.20, 2.56], p = 0.003) and three-point major adverse cardiovascular events (MACE) (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) (HR 1.49 [95% CI 1.20, 1.85], p < 0.001) relative to no positive responses to all questions. Associations were stronger if participants answered positively to all three questions (n = 552, 11%). The addition of the total number of affirmative responses to existing models significantly improved Harrell's C statistic for the cardiovascular composite outcome (0.70 vs 0.71, p = 0.010), continuous net reclassification improvement (+22% [+10%, +31%], p = 0.027) and integrated discrimination improvement (+0.9% [+0.4%, +2.1%], p = 0.007). CONCLUSIONS/INTERPRETATION: We identified three questions from the MNSI that provide additional prognostic information for individuals with type 2 diabetes and CKD and/or CVD. If externally validated, these questions may be integrated into the clinical history to augment prediction of CV events in high-risk individuals with type 2 diabetes.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Seferovic JP, Pfeffer MA, Claggett B, et al. Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trial. Diabetologia. 2017. PMID: 29098323. doi:10.1007/s00125-017-4485-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。